Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy.
OBJECTIVE
ABO blood type is an inherited characteristic that has been associated with the prognosis of several malignancies, but there is little evidence in urothelial carcinoma of the bladder (UCB). The purpose of this study was to evaluate the effect of ABO blood type on mortality in patients with UCB treated with radical cystectomy (RC).


METHODS
Multi-institutional data from 7,906 patients with UCB treated with RC between 1979 and 2012 were retrospectively analyzed. The effect of ABO blood type on UCB-related mortality was evaluated with univariable and multivariable competing-risks regression models.


RESULTS
ABO blood type was O in 3,728 (47%), A in 2,748 (35%), B in 888 (11%), and AB in 532 (7%) patients. Blood type B was associated with a greater likelihood of lymphovascular invasion (P = 0.010) and positive soft tissue margins (P = 0.008). The median follow-up was 41 months. The 5-year cumulative UCB-related mortality rates for blood type O, A, B, and AB were 29.5%, 30.5%, 33.2%, and 25.8%, respectively. In univariable competing-risks regression, patients with blood type B had worse UCB-related mortality than those with blood type O (P = 0.026) and AB (P = 0.020). In multivariable analysis, however, blood type lost its statistical significance.


CONCLUSIONS
Among patients treated with RC, ABO blood type is associated with a statistically significant but clinically insignificant difference in UCB-related mortality. This association was not present in multivariable analysis. Our data therefore suggest no relevant association of ABO blood type with UCB-related prognosis.
Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
Tobias
T
Klatte
Department of Urology, Weill Cornell Medical College, Presbyterian Hospital, New York, NY; Department of Urology, Cochin Hospital, APHP, Paris Descartes University, Paris, France.
Evanguelos
E
Xylinas
Department of Urology, Weill Cornell Medical College, Presbyterian Hospital, New York, NY; Department of Urology, University Hospital Basel, Basel, Switzerland.
Malte
M
Rieken
Department of Urology, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hopitaux de Paris, Faculty of Medicine Pierre et Marie Curie, Institut Universitaire de Cancérologie GRC5, University Paris 6, Paris, France.
Morgan
M
Rouprêt
Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
Harun
H
Fajkovic
Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
Christian
C
Seitz
Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Quebec, Canada.
Pierre I
PI
Karakiewicz
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
Yair
Y
Lotan
Department of Urology, Hospital Motol, Second Faculty of Medicine, Prague, Czech Republic.
Marko
M
Babjuk
Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
Michela
M
de Martino
Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Department of Urology, Weill Cornell Medical College, Presbyterian Hospital, New York, NY. Electronic address: sfshariat@gmail.com.
Shahrokh F
SF
Shariat
D000017:ABO Blood-Group System; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D015653:Cystectomy / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012044:Regression Analysis; D012189:Retrospective Studies; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000097:blood* / Q000401:mortality* / Q000601:surgery
D000017:ABO Blood-Group System; D014408:Biomarkers, Tumor
ABO; Biomarker; Blood group; Blood type; Cystectomy; Prognosis